SCHEDULE 13G/A: BlackRock Discloses 2.0% Passive Stake in Adverum Biotechnologies
Beneficial Ownership Disclosure
BlackRock, Inc. has disclosed a 2.0% passive beneficial ownership stake in Adverum Biotechnologies, Inc., holding 414,485 shares of common stock as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 414,485 shares of Adverum Biotechnologies, Inc. common stock.
- This ownership represents 2.0% of the total outstanding common stock of Adverum Biotechnologies, Inc.
- BlackRock holds sole voting power over 412,045 shares and sole dispositive power over 414,485 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported beneficial ownership.
- BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Adverum Biotechnologies, Inc.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It indicates a passive investment stake.
Future Outlook
NA
Management Comments
- BlackRock, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This Schedule 13G filing is a standard disclosure by a large institutional investor, BlackRock, Inc., indicating its passive beneficial ownership in Adverum Biotechnologies, Inc. Such filings are routine for investment managers holding less than 5% of a company's shares with no intent to influence control, providing transparency on significant institutional holdings within the market.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake, which may contribute to market confidence.
- Management: Awareness of BlackRock's passive holding, but no direct impact on operational or strategic decisions given the nature of a 13G filing.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Date of execution for the Power of Attorney. |
| 2025-04-30 | Date of the previously revoked Power of Attorney. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-07-16 | Date of signature for the Schedule 13G filing. |
Keywords
BlackRock, Adverum Biotechnologies, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.